Last edition
News about "Sang Hoon Lee"
ABL Bio Receives Upfront Payment and Equity Investment from Lilly for Grabody Platform
ABL Bio has secured a total of USD 55 million in funding from Lilly, including a USD 40 million upfront payment and a USD 15 million equity investment, under a license, research and collaboration agreement to advance R&D and expand indications for its Grabody platform.
Sang Hoon Lee | 26/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members